Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
Save for later
Research Tools Catalog
Donate Now
Illustrated close up of DNA.
Resources Save for later

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

    Learn more
  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

    Learn more
  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

    Learn More

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
Clear all
Sort by
Order
Filters
Clear all
Sort by
Order
Sort by
Order
Results (357)
Sort by:
A-ZSort Descending
Most recentInactive Filter
TMEM175 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including 
  • -Q65P (heterozygous and homozygous) - in development, est late 2025
  • -M393T (heterozygous and homozygous)
  • -DOX-NGN2 + TMEM192-HA + Knockout (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative.  
  • TMEM175
Get research tool
Available at The Jackson Laboratory
GBA1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GBA1, including:
  • -K198E (heterozygous and homozygous)
  • -E326K (heterozygous and homozygous)
  • -T369M (heterozygous and homozygous)
  • -N370S (heterozygous and homozygous)
  • -L444P (heterozygous and homozygous) - in development, est late 2025
  • -D448H (heterozygous and homozygous) - in development, est late 2025
  • -D448V (heterozygous and homozygous)
  • -Noncoding rs3115534 (heterozygous and homozygous) - in development, est late 2025
  • -DOX-NGN2 + TMEM192-HA + L444P (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative.  
  • GBA
Get research tool
Available at The Jackson Laboratory
TRPML1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TRPML1, including
  • -F408* (heterozygous and homozygous) - in development, est late 2026
  • -DOX-NGN2 + TMEM192-HA + Knockout (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. 
  • TRPML1
Currently In Development
SNCA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SNCA, including
  • -A30P (heterozygous and homozygous)
  • -A53T (heterozygous and homozygous)
  • -E46K (heterozygous and homozygous)
  • -DOX-NGN2 + TMEM192-HA + A53T (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. 
  • SNCA
  • Alpha-Synuclein
Get research tool
Available at The Jackson Laboratory
ATP13A2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in ATP13A2, including:
  • -T517I (heterozygous and homozygous)
  • -R745H (heterozygous and homozygous) - in development, est late 2026
  • -M854R (heterozygous and homozygous)
  • -c1306 (heterozygous and homozygous)
  • -DOX-NGN2 + TMEM192-HA + c1306 (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). This cell line development project is is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative and the MJFF Targets to Therapies (T2T) Initiative.  Estimated Availability: Late 2026
  • ATP13A2
Currently In Development
USP30 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous of USP30.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated availability: late 2026
  • USP30
Currently In Development
TRPM2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including 
  • rs56379273 (heterozygous and homozygous) - in development, est late 2026
  • Knockout (homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.  
  • TRPM2
Currently In Development
VPS13C Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in VPS13C, including 
  • -R117* (heterozygous and homozygous) - in development, est late 2025
  • -G1389R (heterozygous and homozygous) - in development, est late 2025
  • -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. 
  • VPS13C
Currently in Development
SMPD1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SMPD1, including 
  • -Q294K (heterozygous and homozygous) - in development, est late 2025
  • -L262Rfs*s (heterozygous and homozygous) - in development, est late 2025
  • -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
  • SMPD1
Currently in Development
SMPD1 Antibody
Antibody
Rabbit monoclonal antibody directed against human SMPD1. Developed for use in immunoblotting, immunocytochemistry, and immunoprecipitation applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Anticipated Availability: Q4 2027
  • SMPD1
Currently In Development
Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 
Tools Catalog FAQ
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.